US Congress Makes Another Push for Drug Pricing Regulation
With tough odds in the upcoming midterm elections in mind, Democrats in the US Senate are making another push for drug pricing regulation. The latest attempt would limit the out-of-pocket drug costs to $2,000 and let Medicare negotiate drug prices. The proposal would also let the Department of Health and Human Services (HHS) select a small set of drugs for price negotiation, beginning with 10 in 2026 and steadily increasing as time passes.
US Senate Advances its Version of Accelerated Approval Reforms
Right on the heels of similar legislation in the US House of Representatives, the Senate is pushing forward its version [...]
Congress Begins Two-Week Recess with No Decision on COVID-19 Relief Bill
Members of the US Congress have left for their 2-week recess with progress stalled on the next round of COVID-19 [...]
Senate Republicans and Democrats Close to Agreement on $10 Billion COVID-19 Aid
Republicans and Democrats in the US Senate have reached an “agreement in principle” over a $10 billion COVID-19 aid package, [...]
Democrats Prepare for Next Attempt to Lower Prescription Drug Prices
On the heels of Democrats’ recent failure to pass the Build Back Better bill, Senate Majority Leader Chuck Schumer (D-N.Y.) [...]
Democrats Torn over Insulin Cost Cap
Sen. Raphael Warnock’s (D-Ga.) proposed bill to cap out-of-pocket insulin prices at $35 per month is facing scrutiny from other [...]
Robert Califf Confirmed as FDA Commissioner
In a narrow 50-46 vote, Robert Califf has officially been confirmed as the Food and Drug Administrations new commissioner. This [...]
Final Vote on Califf for FDA Commissioner
The Senate votes on the confirmation of Robert Califf for FDA Commissioner today amid ongoing political turmoil. Although largely divided [...]
Robert Califf’s Candidacy for FDA Commissioner Faces Uncertainty
The Biden Administration's nominee for FDA commissioner is on shaky ground as he faces skepticism from some Democrats and a [...]
Drug Pricing Bill Unlikely With Split Congress
The Republican-led Senate is not likely not go along with Democrats' plan to let Medicare leverage its substantial buying power [...]
